menu
    • menu

    Company profile for Novartis Pharmaceuticals Corporation

    Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals ...
    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals Corporation, we believe that all Americans deserve access to quality health care, including prescription medicines, health education about their disease or condition

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Novartis Pharmaceuticals CorporationSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Klybeckstrasse 141, CH-4057, Basel
    Telephone
    Telephone
    +41 61 324 11 11
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novartis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI South East Asia

    Not Confirmed

    envelop Contact Supplier

    CPhI South East Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 1327

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaYour Global Ally in the Pharmaceutical IndustryYour Global Ally in the Pharmaceutical Industry

    Your Global Ally in the Pharmaceutical Industry
    Your Global Ally in the Pharmaceutical Industry

    reelYour Global Ally in the Pharmaceutical Industry

    This PharmaReel highlights Gentec Pharmaceutical's expertise in generic APIs, HPAPIs, and prostaglandins with more than 30 years of experience. Operating from EU-GMP-certified facilities, the company exports to over 70 countries worldwide.

    Impressions: 399

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 468

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis Loses Bid to Block Us Entresto Generic Through 2026
    Novartis Loses Bid to Block Us Entresto Generic Through 2026

    14 Jul 2025

    // REUTERS

    https://www.reuters.com/legal/litigation/novartis-loses-bid-block-us-entresto-generic-through-2026-2025-07-11/

    REUTERS
    14 Jul 2025
    Share Share
    Novartis inks $175M option deal for Sironax’s blood-brain barrier
    Novartis inks $175M option deal for Sironax’s blood-brain barrier

    10 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sironax-grants-novartis-exclusive-option-to-acquire-its-brain-delivery-platform-while-retaining-rights-to-advance-selected-therapeutic-assets-302500323.html

    PR NEWSWIRE
    10 Jul 2025
    Share Share
    Novartis gets Approval for First malaria drug for babies
    Novartis gets Approval for First malaria drug for babies

    08 Jul 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-gets-approval-first-malaria-drug-babies-children-2025-07-08/

    REUTERS
    08 Jul 2025
    Share Share
    Novartis Drug Cosentyx Fails Late-Stage Trial for Artery Disease
    Novartis Drug Cosentyx Fails Late-Stage Trial for Artery Disease

    05 Jul 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-drug-cosentyx-fails-late-stage-trial-artery-disease-2025-07-03/

    REUTERS
    05 Jul 2025
    Share Share
    Novartis Pens ProFound Pact for Cardiovascular Disease Targets
    Novartis Pens ProFound Pact for Cardiovascular Disease Targets

    27 Jun 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-pens-profound-pact-offering-750m-biobucks-cardiovascular-target

    FIERCE BIOTECH
    27 Jun 2025
    Share Share
    Novartis completes acquisition of Regulus Therapeutics
    Novartis completes acquisition of Regulus Therapeutics

    25 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/25/3105176/0/en/Novartis-completes-acquisition-of-Regulus-Therapeutics.html

    GLOBENEWSWIRE
    25 Jun 2025
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Cadent Therapeutics and get a quotation

    Cadent Therapeutics is a supplier offers 70 products (APIs, Excipients or Intermediates).

    Find a price of Pentetreotide bulk with DMF, JDMF offered by Cadent Therapeutics

    Find a price of Valsartan bulk with DMF, CEP offered by Cadent Therapeutics

    Find a price of Amlodipine Besylate bulk with CEP offered by Cadent Therapeutics

    Find a price of Baclofen bulk with DMF offered by Cadent Therapeutics

    Find a price of Cefepime Hydrochloride bulk with JDMF offered by Cadent Therapeutics

    Find a price of Ceftriaxone bulk with JDMF offered by Cadent Therapeutics

    Find a price of Cyclosporine bulk with JDMF offered by Cadent Therapeutics

    Find a price of Fluvastatin bulk with DMF offered by Cadent Therapeutics

    Find a price of Glycolide - lactide copolymer bulk with DMF offered by Cadent Therapeutics

    Find a price of Letrozole bulk with CEP offered by Cadent Therapeutics

    Find a price of NAFTIFINE HCL bulk with DMF offered by Cadent Therapeutics

    Find a price of Penicillin G Benzathine bulk with JDMF offered by Cadent Therapeutics

    Find a price of Terbinafine bulk with DMF offered by Cadent Therapeutics

    Find a price of Topotecan Hydrochloride bulk with DMF offered by Cadent Therapeutics

    Find a price of Benzonatate bulk offered by Cadent Therapeutics

    Find a price of Bisoctrizole bulk offered by Cadent Therapeutics

    Find a price of Chlorthalidone bulk offered by Cadent Therapeutics

    Find a price of Clofazimine bulk offered by Cadent Therapeutics

    Find a price of Clomipramine Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Edotreotide bulk offered by Cadent Therapeutics

    Find a price of Eudragit Rs bulk offered by Cadent Therapeutics

    Find a price of Methylphenidate Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Naphazoline Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Pyrilamine bulk offered by Cadent Therapeutics

    Find a price of Pyrilamine Maleate bulk offered by Cadent Therapeutics

    Find a price of Rifampicin bulk offered by Cadent Therapeutics

    Find a price of Thurfyl Nicotinate bulk offered by Cadent Therapeutics

    Find a price of TESSALON DRUG SUBSTANCE bulk offered by Cadent Therapeutics

    Find a price of CGP 17,582B bulk offered by Cadent Therapeutics

    Find a price of PERSONNEL, FACILS & GEN OPERATING PROCEDURES AT EAST HANOVER, NJ. bulk offered by Cadent Therapeutics

    Find a price of 2(2'-HYDROXY-5-METHYLPHENYL) BENZOTRIAZOLE bulk offered by Cadent Therapeutics

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURE IN ORLEANS-LA SOURCE, FRANCE. bulk offered by Cadent Therapeutics

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GRIMSBY, UK bulk offered by Cadent Therapeutics

    Find a price of ADJUVANT CGP 11637:TOXICITY STUDIES & RESULTS CONDUCTED IN EUROPEAN FA bulk offered by Cadent Therapeutics

    Find a price of PULMONARY DRUG DELIVERY SYSTEM (PDDS) CLINICAL bulk offered by Cadent Therapeutics

    Find a price of TINUVIN 326 bulk offered by Cadent Therapeutics

    Find a price of FACILITY AND OPERATING PROCEDURES IN DORVAL, QUEBEC, CANADA bulk offered by Cadent Therapeutics

    Find a price of STARTING MATERIALS 1 & 3, IN NEW JERSEY AND SWITZERLAND bulk offered by Cadent Therapeutics

    Find a price of CGP LL637 ADJUVANT--CHEMISTRY & GMP bulk offered by Cadent Therapeutics

    Find a price of PULMOSPHERE(R) PLACEBO INHALATION POWDER bulk offered by Cadent Therapeutics

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN STEIN, SWITZERLAND. bulk offered by Cadent Therapeutics

    Find a price of Alpelisib bulk offered by Cadent Therapeutics

    Find a price of Asciminib bulk offered by Cadent Therapeutics

    Find a price of Atorvastatin bulk offered by Cadent Therapeutics

    Find a price of Dabrafenib Mesylate bulk offered by Cadent Therapeutics

    Find a price of Deferasirox bulk offered by Cadent Therapeutics

    Find a price of Diclofenac Diethylamine bulk offered by Cadent Therapeutics

    Find a price of Everolimus bulk offered by Cadent Therapeutics

    Find a price of Fingolimod Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Fluvastatin Sodium bulk offered by Cadent Therapeutics

    Find a price of Hydrochlorothiazide bulk offered by Cadent Therapeutics

    Find a price of Indacaterol Maleate bulk offered by Cadent Therapeutics

    Find a price of Iptacopan Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Ketotifen Fumarate bulk offered by Cadent Therapeutics

    Find a price of Lithium Carbonate bulk offered by Cadent Therapeutics

    Find a price of Mycophenolate Mofetil bulk offered by Cadent Therapeutics

    Find a price of Mycophenolate Sodium bulk offered by Cadent Therapeutics

    Find a price of Nilotinib bulk offered by Cadent Therapeutics

    Find a price of Osilodrostat Phosphate bulk offered by Cadent Therapeutics

    Find a price of Oxcarbazepine bulk offered by Cadent Therapeutics

    Find a price of Pimecrolimus bulk offered by Cadent Therapeutics

    Find a price of Ribociclib bulk offered by Cadent Therapeutics

    Find a price of Rivastigmine bulk offered by Cadent Therapeutics

    Find a price of Rivastigmine Tartrate bulk offered by Cadent Therapeutics

    Find a price of Tacrolimus bulk offered by Cadent Therapeutics

    Find a price of Terbinafine Hydrochloride bulk offered by Cadent Therapeutics

    Find a price of Trametinib bulk offered by Cadent Therapeutics

    Find a price of Valsartan bulk offered by Cadent Therapeutics

    Find a price of Vildagliptin bulk offered by Cadent Therapeutics

    Find a price of Ashmini hydrochloride bulk offered by Cadent Therapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search